1. Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)
   Osamu Hiranuma et al, 2019, Clinical Lung Cancer CrossRef
2. Malignant pleural effusions for cancer genotyping: A matter of trans-pleural traffic of cell-free tumor DNA
   Gábor Méhes et al, 2022, Molecular and Cellular Probes CrossRef
3. Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
   Makoto Hibino et al, 2022, JTO Clinical and Research Reports CrossRef
4. Time interval from cigarette smoke exposure to blood donation and markers of inflammation: should a smoking cut-off be designated?
   Emmanouil K. Symvoulakis et al, 2010, Xenobiotica CrossRef
5. Saikosaponin-d regulates angiogenesis in idiopathic pulmonary fibrosis through angiopoietin/Tie-2 pathway
   Yan Wu et al, 2023, Acta Histochemica CrossRef
6. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy
   Zhangqiang Xiang et al, 2022, Annals of Medicine CrossRef
7. Malignant Pericardial Effusion in Ovarian Malignancy: A Treatable Oncologic Emergency
   Tamar Perri et al, 2015, The Journal of Emergency Medicine CrossRef
8. Role of VEGF-stromal cell–derived factor-1α/CXCL12 axis in pleural effusion of lung cancer
   Foteini Economidou et al, 2010, Journal of Receptors and Signal Transduction CrossRef
9. Diagnostic accuracy of endostatin for malignant pleural effusion: A clinical study and meta-analysis
   Panwen Tian et al, 2015, Postgraduate Medicine CrossRef
10. Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice
    Shen-Cun Fang et al, 2015, Medical Oncology CrossRef
11. Prognostic value of pro‐inflammatory cytokine and pro‐angiogenesis factor in differentiating malignant from benign exudative effusion
    Radwa Ahmed Elhefny et al, 2017, The Clinical Respiratory Journal CrossRef
12. Objective Thoracoscopic Criteria in Differentiation between Benign and Malignant Pleural Effusions
    Mohamed Ellayeh et al, 2022, Respiration CrossRef
13. Lipoprotein profile of pleural and peritoneal transudates in dogs and cats
    Flavio H. Alonso et al, 2022, Journal of Veterinary Internal Medicine CrossRef
14. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment
    Do-Young Choi et al, 2014, PROTEOMICS CrossRef
15. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway
    Meng-Feng Tsai et al, 2015, Scientific Reports CrossRef
16. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion
    Hong Tao et al, 2018, Thoracic Cancer CrossRef
17. Correlation analysis between eGFRcys and SXscore in patients with diabetes
    ZHONG YONG et al, 2014, Experimental and Therapeutic Medicine CrossRef
18. Bevacizumab+Paclitaxel Therapy for Advanced/Recurrent Breast Cancer
    Masanori SANDO et al, 2015, Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) CrossRef